ADMA Biologics Inc (NASDAQ:ADMA)
| Market Cap | 2.94B-14.6% |
| Revenue (ttm) | 519.15M+6.3% |
| Net Income | 182.41M-12.9% |
| EPS | 0.77-10.5% |
| Shares Out | 223.99M |
| PE Ratio | 16.61 |
| Forward PE | 13.91 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,689,244.871 |
| Open | 12.01 |
| Previous Close | 10.48 |
| Day's Range | 11.90 - 13.23 |
| 52-Week Range | 7.21 - 20.46 |
| Beta | 0.77 |
| Analysts | Buy |
| Price Target | 19.00(+44.76%) |
| Earnings Date | Feb 24, 2027 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About ADMA
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating ADMA in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 24, 2027Earnings report
Ask Barron about ADMA
$ADMA stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ADMA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ADMA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ADMA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ADMA Revenue by Segment or Geography
| Segment | Revenue | % of All |
|---|---|---|
| Income (loss) before taxes | $65.60M | 57.39% |
| Cost of product revenue | $41.19M | 36.03% |
| Selling, marketing and distribution | $7.53M | 6.59% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New ADMA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ADMA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ADMA
| ETF | Est. Holding Size |
|---|---|
| IJRiShares Core S&P Small-Cap ETF | $141.80M |
| FBTFirst Trust NYSE Arca Biotechnology Index Fund | $105.95M |
| VTIVanguard Morningstar Total Stock Market ETF | $65.39M |
| IWMiShares Russell 2000 ETF | $63.15M |
| XBIState Street SPDR S&P Biotech ETF | $52.62M |
| VXFVanguard Extended Market ETF | $25.37M |
Estimated from each fund’s disclosed top holdings × AUM
ADMA Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ADMA’s recent data — informational, not investment advice
What’s Behind the Score
News check: Mixed coverage with slight bullish lean; analyst views suggest positive investment case despite recent stock underperformance.